A phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the pharmacokinetics, safety, and tolerability of oral ceftibuten in healthy adult subjects

• Published in: Antimicrobial agents and chemotherapy Vol. 68; no. 1; p. e0109923
• Main Authors: Hernández-Mitre, María Patricia, Wallis, Steven C, Morgan, Elizabeth E, Dudley, Michael N, Loutit, Jeffery S, Griffith, David C, Roberts, Jason A
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 10.01.2024
• Subjects: Administration, Oral; Adult; Antimicrobial Chemotherapy; Area Under Curve; Ceftibuten; Dose-Response Relationship, Drug; Double-Blind Method; Healthy Volunteers; Humans; Pharmacology; pharmacokinetics; phase I; ceftibuten; safety; tolerability
• ISSN: 0066-4804; 1098-6596
• DOI: 10.1128/aac.01099-23

This was a phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of oral ceftibuten to describe the pharmacokinetics (PK) of ceftibuten (administered form) and ceftibuten (metabolite), and to describe safety and tolerability at higher than licensed doses. Subjects received single 400, 600, or 800 mg doses of ceftibuten on Days 1 and 4, followed by 7 days of twice-daily dosing from Days 4 to 10. Non-compartmental methods were used to describe parent drug and metabolite PK in plasma and urine. Dose proportionality was examined using , AUC , and AUC . Accumulation was calculated as the ratio of AUC on Days 4 and 10. Adverse events (AEs) were monitored throughout the study. Following single ascending doses, mean - and ceftibuten were 17.6, 24.1, and 28.1 mg/L, and 1.1, 1.5, and 2.2 mg/L, respectively; -ceftibuten urinary recovery accounted for 64.3%-86.9% of the administered dose over 48 h. Following multiple ascending doses, mean - and ceftibuten were 21.7, 28.1, and 38.8 mg/L, and 1.4, 1.9, and 2.8 mg/L, respectively; -ceftibuten urinary recovery accounted for 72.2%-96.4% of the administered dose at steady state. The exposure of and ceftibuten increased proportionally with increasing doses. - and ceftibuten accumulation factor was 1.14-1.19 and 1.28-1.32. The most common gastrointestinal treatment emergent AEs were mild and resolved without intervention. Ceftibuten was well tolerated. Dose proportionality and accumulation of - and -ceftibuten were observed. These results support the ongoing development of ceftibuten at doses up to 800 mg twice-daily. (The study was registered at ClinicalTrials.gov under the identifier NCT03939429.).